{"id":"W4232382020","doi":"10.1007/978-3-319-48066-4_13","title":"Pembrolizumab","year":2016,"lang":"id","type":"book-chapter","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pembrolizumab; Nivolumab; Medicine; Ipilimumab; Monoclonal antibody; Melanoma; Oncology; Metastatic melanoma; Adverse effect; Clinical trial; Drug; Monoclonal; Internal medicine; Antibody; Immunotherapy; Pharmacology; Cancer research; Immunology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001678244,0.000572069,0.00034099,0.0007371033,0.0003163582,0.001362044,0.0003445876,0.000651178,0.04473847],"category_scores_gemma":[0.0004184481,0.000161525,0.0001900362,0.0005579907,0.0002991057,0.001308652,0.000643378,0.001730214,0.02571248],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007397129,"about_ca_system_score_gemma":0.0005106272,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006415069,"about_ca_topic_score_gemma":0.001922994,"domain_scores_codex":[0.9999211,0.00001077033,0.000003682004,0.00001356993,0.00004352487,0.000007318016],"domain_scores_gemma":[0.9999316,0.00002886803,0.000006242548,0.000006015234,0.00001534899,0.00001198876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002717601,0.00003281493,0.00003374184,0.0002550481,0.000004959064,0.00008016602,0.00004940426,0.0001701615,0.001194566,0.02846078,0.461104,0.5085871],"study_design_scores_gemma":[0.00000329749,0.000005131091,0.00003561303,0.0000846093,0.000001940721,0.0001495358,0.000006852009,0.00004583518,0.0001875683,0.004280546,0.9951972,0.000001859959],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.0008745149,0.1817407,0.008217729,0.01351526,0.01083232,0.00005387694,0.000580652,0.0004741725,0.7837107],"genre_scores_gemma":[0.004389173,0.07451448,0.002981006,0.004761877,0.002311166,0.00005288737,0.0003096127,0.00009462015,0.9105853],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.04473847,"threshold_uncertainty_score":0.1496651,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0219461870285852,"score_gpt":0.2614806494050266,"score_spread":0.2395344623764414,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}